Skip to content

News Releases

Filter Releases
 
News Releases
Date Title and Summary View
Mar 8, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/08/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2011. The net loss for the fourth quarter and year ended December 31, 2011 was $5.3 million and $25.7 million, respectively. As of December 31, 2011, Thresho...
Mar 6, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/06/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that a Late-Breaking clinical abstract has been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held on March 31st - April 4th 2012, in Chicago, IL. The presentation will ...
Feb 24, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/24/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Threshold's Chief Executive Officer, is scheduled to present at the 32nd Annual Cowen Health Care Conference in Boston on Tuesday, March 6, 2012 at 10:00AM EST. A live webcast of the prese...
Feb 21, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/21/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) Primary endpoint of Progression Free Survival was met with hazard ratio of 0.61 (p = 0.005). The combination therapy was well tolerated with a safety profile consistent with prior studies. Threshold Pharmaceu...
Feb 17, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/17/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the appointment of Tillman Pearce, M.D. as its Chief Medical Officer. In this position, Dr. Pearce will oversee the development of Threshold's TH-302, a clinical stage hypoxia-targeted cancer therapeutic currently being evalua...
Feb 3, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/03/12 -- Threshold Pharmaceuticals, Inc (NASDAQ: THLD) Threshold to receive $25 million upfront, plus further potential milestones and royalties Deal provides Threshold option to co-commercialize in the United States Phase 3 trial in soft tissue sarcoma on-going and randomi...
Page: First Previous
...